Yes, Behçet's syndrome definitively causes oral ulcers—they are a hallmark manifestation of the disease.
Oral ulcers are the most characteristic and often the first clinical manifestation of Behçet's syndrome, occurring in virtually all patients and serving as a mandatory criterion for diagnosis 1. These recurrent aphthous ulcers are not merely associated with the condition; they are a defining feature that distinguishes Behçet's from other systemic vasculitides.
Clinical Characteristics of Oral Ulcers in Behçet's
The oral ulcers in Behçet's syndrome present with specific patterns:
- Minor aphthous ulcers are most common, appearing as solitary or multiple lesions 2
- They recur repeatedly throughout the disease course, causing significant pain and functional disability 2
- The mean age of first oral ulcer appearance is approximately 29-30 years, often preceding the formal diagnosis of Behçet's by several years 2
- These ulcers are characteristically the first signs of Behçet's disease and are critical for early recognition 3
Impact on Quality of Life
The oral ulcers significantly impair patients' quality of life beyond simple discomfort:
- Pain severity typically exceeds functional disability on composite indices 2
- Patients experience difficulties eating, feel tense and irritable, and report less satisfying lives 2
- Female gender, multiple ulcers, and buccal mucosa location are associated with more severe pain and poorer quality of life 2
- When chronic oral ulceration causes scarring, vigorous treatment is required to prevent oropharyngeal narrowing 1
Diagnostic Significance
Oral ulcers are mandatory for diagnosis under the International Criteria for Behçet's Disease (ICBD) 4, 5. While oral aphthous ulcers are common in the general population, the diagnosis of Behçet's should be considered when recurrent aphthous ulcers are accompanied by other systemic manifestations such as genital ulcers, ocular involvement, skin lesions, or vascular manifestations 4.
Treatment Approach
According to the 2018 EULAR guidelines 1:
- Topical steroids should be used for acute treatment of oral ulcers (Level of evidence: IB; strength of recommendation: A)
- Colchicine should be tried first for prevention of recurrent mucocutaneous lesions (Level of evidence: IB; strength of recommendation: A)
- For refractory cases, drugs such as azathioprine, thalidomide, interferon-alpha, TNF-alpha inhibitors, or apremilast should be considered 1
- Apremilast has demonstrated superiority over placebo for oral ulcers in recent high-quality RCTs 6
- Roflumilast (a PDE4 inhibitor) showed 71.7% positive response rates at 12 weeks for refractory oral ulcers, with 30.4% achieving complete remission, though gastrointestinal adverse events were common (71.7%) 7
Common Pitfalls
- Do not dismiss recurrent oral ulcers as simple aphthous stomatitis without evaluating for systemic manifestations of Behçet's
- Recognize that oral ulcers may be misattributed to drug reactions (e.g., anti-tuberculous therapy) when Behçet's is the actual underlying cause 4
- The absence of HLA-B51 or negative pathergy test does not exclude Behçet's syndrome 5